Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101
Phase II SUSTAIN data presented at ASH show a statistically significant reduction in sickle cell pain crises for SEG101 (crizanlizumab), a potential blockbuster for Novartis, which recently said it will pay up to $665m for the antibody’s developer.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA approval is likely for Emmaus' sickle cell drug L-glutamine this summer, representing the first new product for the disease since 1998 – a decision FDA advisory committee panelists hope will spur more innovation.
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.